Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18130555 | 0.97 | GAA (0.47) | ENPP2GAA | |
| SCHEMBL13460264 | 0.89 | ENPP2 (0.41) | ENPP2GAA | |
| SCHEMBL18130508 | 0.86 | ENPP2 (0.46) | ENPP2GAA | |
| SCHEMBL1919527 | 0.85 | ENPP2 (0.42) | ENPP2GAA | |
| SCHEMBL18130539 | 0.83 | ENPP2 (0.48) | ENPP2 | |
| SCHEMBL1920866 | 0.81 | KDM4E (0.46) | — | |
| SCHEMBL18130423 | 0.81 | ENPP2 (0.56) | ENPP2 | |
| SCHEMBL1919523 | 0.81 | ENPP2 (0.41) | ENPP2 | |
| SCHEMBL18130421 | 0.81 | ENPP2 (0.70) | ENPP2 | |
| SCHEMBL1919429 | 0.81 | ENPP2 (0.55) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-107428754-B | Bicyclic quinazolinone derivatives | 豪夫迈·罗氏有限公司 | 2020-07-31 | — | — | CN | disclosed |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3280707-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2018-02-14 | — | — | EP | disclosed |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2016162390-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-13 | — | — | WO | disclosed |
| US-8299023-B2 | Neuropeptide-2 receptor (Y-2R) agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299023-B2 | Neuropeptide-2 receptor (Y-2R) agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299023-B2 | Neuropeptide-2 receptor (Y-2R) agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2326666-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010031707-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | DANHO WALEED | 2010-03-18 | — | — | US | disclosed |
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | DANHO WALEED | 2010-03-18 | — | — | US | disclosed |
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | DANHO WALEED | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | NPY2R, NPY1R, NPY4R | ENPP2 382/4885GAA 3499/4885 |
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | ENPP2 4284/4885GAA 4283/4885 |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | ENPP2 4284/4885GAA 4283/4885 |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | BRD4, BICRA, NDUFC2 | ENPP2 4284/4885GAA 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.